Skip to content
Tuesday 11 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE
MorningWire

European business, markets and politics

FTSE 100
10,844.19
-0.17%
DAX
26,391.42
+0.26%
CAC 40
8,714.94
-0.13%
STOXX 50
6,551.22
+0.24%
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
More
GermanyFranceBankingAIEnergyFintechPropertyCapital Markets
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
  • DE

Astrazeneca

  • Suspected North Korean hackers ‘target’ Covid-19 vaccine maker Astrazeneca

    November 27, 2020

    Suspected North Korean hackers are said to have made multiple attempts to hack into the computer systems of British Covid-19 vaccine maker Astrazeneca. Hackers posed as recruiters on Linkedin and Whatsapp and approached Astrazeneca staff with fake job offers, Reuters reported, citing sources. They then sent documents purporting to be job descriptions that were teeming [...]

  • Government urges regulator to approve Astrazeneca-Oxford vaccine for emergency supply

    November 27, 2020

    The government has formally asked the UK’s medicines regulator to authorise Astrazeneca and Oxford University’s coronavirus vaccine for emergency supply. If the vaccine is approved, it could speed up the rollout of the treatment across the UK. Regulators will begin to assess the vaccine when they receive full data from ongoing trials being carried out [...]

  • Astrazeneca mulling extra vaccine trial to ‘validate’ efficacy after results confusion

    November 26, 2020

    Astrazeneca’s chief executive today said that the firm was likely to carry out another trial of its potential coronavirus vaccine after doubts were raised as to its efficacy. The admission, which was reported by Bloomberg, came after reports that a number of participants had received the wrong dosage during the trials. When the FTSE 100 [...]

  • Analysis: Why dismay over the Astrazeneca vaccine is misplaced

    November 23, 2020

    Astrazeneca and the University of Oxford’s announcement this morning that their coronavirus vaccine proved 70 per cent effective in late-stage trials would have been bombastic three weeks ago.  Alas, timing is everything — and in that time the world has seen a new US President, dozens of national lockdowns and two other (more) successful vaccine [...]

  • Could anti-vaxxers be barred from offices, pubs and gyms?

    November 22, 2020

    Banning Covid vaccine refusers from offices, restaurants and other venues may lead to expensive discrimination claims, a leading lawyer has warned, even though it is not unlikely that care operators and the NHS may ultimately bar vaccine refusing staff for safety reasons. With the UK moving closer to the rollout of a Coronavirus vaccine, to [...]

  • Coronavirus: Phase one vaccine rollout will protect ‘99 per cent’ of UK’s at-risk population

    November 11, 2020

    The UK’s top health officials today announced the priority list for vaccination against coronavirus, after health secretary Matt Hancock yesterday said the NHS is preparing to roll out Pfizer’s Covid vaccine from December. Speaking at a Downing Street Covid briefing this morning led by deputy chief medical officer Jonathan Van-Tam, the Joint Committee on Vaccination [...]

  • Astrazeneca boosts revenue but misses first vaccine delivery target

    November 5, 2020

    Pharma giant Astrazeneca has seen its sales and revenue rise for the year to date despite the ongoing disruption from the coronavirus pandemic. The FTSE blue-chip said that revenue increased eight per cent to £19.2bn in the first nine months of the year, while sales rose nine per cent. The company, which is working with [...]

  • Coronavirus: NHS boss confirms health service is preparing for vaccine by Christmas

    November 4, 2020

    The NHS is preparing to distribute potential Covid-19 vaccines in time for Christmas, the head of the health service announced today. Simon Stevens, chief executive of the NHS, said medical chiefs were drawing up plans for wide-scale rollout of a potential vaccine over the next two months, in case one of them is ready in [...]

  • Weekly outlook, 2-6 November: FTSE heavyweights in spotlight as election day arrives

    November 2, 2020

    It’s election day at last, and while the outcome of Tuesday’s vote in the US will drive the headlines for much of this week and beyond, there’s still a full slate of results and economic updates in store for UK markets. With coronavirus cases now surging at an alarming rate, Boris Johnson has announced a [...]

  • Astrazeneca and Pfizer vaccines under accelerated review by drugs regulator

    October 30, 2020

    The UK’s drugs regulator has reportedly begun an accelerated review of coronavirus vaccine candidates developed by Astrazeneca and Pfizer. Bloomberg reported that the Medicines and Healthcare products Regulatory Agency (MHRA) have already commenced ongoing reviews of both vaccines. A source familiar with the trial confirmed to Bloomberg that Pfizer’s treatment was under review, although this [...]

Posts pagination

  • Previous
  • Page 1
  • …
  • Page 16
  • Page 17
  • Page 18
  • Page 19
  • Page 20
  • …
  • Page 27
  • Next

Trending Articles

  • Five-star Mayfair hotel hit with HMRC winding-up petition

  • Nottingham Forest owner Marinakis sues Crystal Palace for defamation

  • Back to basics: Sainsbury’s gradual retreat from the British high street

  • Hargreaves Lansdown orders staff back to office

  • As it happened: Intel, Arm shares slide; Oil climbs higher

MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Business

  • Markets
  • Banking
  • Technology
  • Energy
  • Property
  • Fintech

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook